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Multifocal Pupillography Identifies
Ranibizumab-Induced Changes in Retinal Function for
Exudative Age-Related Macular Degeneration
Faran Sabeti,1 Ted Maddess,1 Rohan W. Essex,1,2 and Andrew C. James1
PURPOSE. To investigate the efficacy of multifocal pupillo-
graphic objective perimetry (mfPOP) to quantify the effects of
intravitreal ranibizumab injection for choroidal neovasculariza-
tion (CNV) secondary to exudative age-related macular degen-
eration (AMD).
METHODS. mfPOP visual fields from 20 patients with unilateral
exudative AMD treated with intravitreal ranibizumab were
measured before and after 3 months of treatment and were
compared with that in 30 normal subjects. Two stimulus types
consisting of ensembles of 24 or 44 independent stimuli per
eye had a mean presentation interval at each region of 1
second. Pupil responses were recorded with video cameras
under infrared illumination. Multiple linear models were fitted
to contraction amplitudes and delay to peak responses, to
determine the independent effects of exudative AMD before
and after ranibizumab therapy.
RESULTS. After 3 months of treatment, mean additional re-
sponse delays compared to normal subjects for the 24-region
stimulus improved significantly (P  5  109) from a mean
of 18.82  3.0 ms at baseline to 7.45  3.15 ms. The mean
effect of exudative AMD at baseline decreased constriction
amplitude by 1.11  0.24 dB (P  0.00001) with little
improvement after ranibizumab therapy. Small pretreatment
elevations of extrafoveal sensitivity correlated with improve-
ments in central retinal thickness (CRT) after treatment (P 
0.0005).
CONCLUSIONS. Improvements in mfPOP contraction amplitudes
and time to peak responses were measured in eyes treated with
intravitreal ranibizumab; however, response delays appeared
to be the most indicative of functional improvement. Confir-
mation of hypersensitivity in the extrafoveal field in a larger
group may support this finding as a prognostic marker for good
treatment outcomes. (Invest Ophthalmol Vis Sci. 2012;53:
253–260) DOI:10.1167/iovs.11-8004
Choroidal neovascularization (CNV) secondary to age-re-lated macular degeneration (AMD) is the leading cause of
severe vision loss in adults in the Western world.1 The trigger
for new blood vessel growth is associated with the release of
vascular endothelial growth factor (VEGF).2,3 The subsequent
proliferation of CNV begins the destructive changes in retinal
morphology and initiates the symptoms associated with exu-
dative AMD. Recent pharmaceutical therapies have therefore
focused on inhibiting VEGF expression. One such anti-VEGF
therapy, ranibizumab (Lucentis; Novartis, North Ryde, NSW,
Australia) has been shown to cause regression of CNV.4,5
Traditionally, indications for treatment, and retreatment
have been determined by measuring best corrected visual acu-
ity (BCVA) and changes in retinal structures with optical co-
herence tomography (OCT). However, good correlation be-
tween morphologic change after ranibizumab therapy and
BCVA is not always present.6 Particularly, early recurrence of
disease after treatment often does not affect BCVA, suggesting
that visual acuity may not be the best measure of visual func-
tion. Alternative means of evaluating retinal sensitivity may
identify disease activity earlier or identify which subjects will
benefit from treatment.
Central retinal sensitivity, as measured by perimetry, has
been shown to improve significantly with ranibizumab treat-
ment alone6,7 and in combination with photodynamic ther-
apy.8 Field loss identified by multifocal pupillographic objec-
tive perimetry (mfPOP) has been shown to correlate highly
with perimetric visual field loss.9,10 Our laboratory has com-
bined mfPOP and so-called spatially sparse stimuli from
mfVEPs11,12 to deliver high diagnostic accuracy in glaucoma
and early-stage diabetic retinopathy.13,14 More recently, we
have shown that higher density mfPOP stimulus arrays tailored
for assessing the macula are feasible,15 and these have pro-
vided excellent diagnostic accuracy in early-stage AMD (Sabeti
F, et al. IOVS 2010;51:ARVO E-Abstract 2794).
In this study, we examined the effects of intravitreal ranibi-
zumab therapy on visual function assessed by the new macular
mfPOP stimuli in patients with CNV secondary to AMD. In
particular, we evaluated changes in regional sensitivity and
response delay before and after 3 months of treatment and
whether these can predict if treatment will be effective.
METHODS
Patient Selection
This study included 20 patients with unilateral exudative AMD re-
cruited from the ophthalmology department at The Canberra Hospital
(Table 1). The affected eyes included 13 with occult and 7 with
predominantly classic choroidal neovascularization (CNV). There were
14 women and 6 men, mean age (SD) 78.8  7.2 years. The subjects
were assessed for their suitability for ranibizumab injections after
BCVA, fundus biomicroscopy, fluorescein angiography, and OCT (Cir-
rus: Carl Zeiss Meditec, Inc., Dublin, CA). Those subjects initially
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received monthly intravitreal injections of 0.5 mg ranibizumab for 3
months. Patients were excluded from the study if they had co-existing
ocular or systemic pathology affecting visual function. Thirty control
subjects (11 men, 19 women; mean age, 71.0  6.0 years) were
recruited and given a thorough eye examination involving detailed
history, frequency-doubling perimetry C-20 field tests, slit lamp exam-
ination of the anterior segment, fundus biomicroscopy and applanation
tonometry. The normal controls were required to have BCVA of 6/6 or
better and no history of ocular surgery or disease. The study was
conducted according to the tenets of the Declaration of Helsinki. All
subjects gave informed written consent, and the study adhered to the
requirements of the Australian National University’s Human Experi-
mentation Ethics Committee (protocol 2010/194).
Multifocal Pupillography Stimuli and Recording
In the present study, all subjects were tested with two randomized
stimulus protocols using a prototype version of an FDA-approved field
analyzer (TrueField Analyzer; Seeing Machines Ltd., Acton, ACT, Aus-
tralia). Testing occurred at baseline, on the same day as the first
injection before dilation, and after three consecutive months of treat-
ment. Our experimental design was chosen because earlier studies
have demonstrated stabilization of BCVA from 3 months.5,16 We have
described the mfPOP technique in detail elsewhere.13–15,17,18 The
following is a brief account of the stimulus properties used in this
study. The yellow multifocal stimuli were presented to each eye inde-
pendently (dichoptic stimulation) on two LCD displays at optical
infinity. This technique allows for afferent and efferent defects to be
measured at all visual field locations.14 The stimulus ensemble con-
sisted of a somewhat overlapping 44-region (O44) and a nonoverlap-
ping 24-region (T24) dartboard layout (Fig. 1), extending from fixation
to 15° eccentricity. Details of these macular stimuli are given else-
where.15 Large, somewhat overlapping stimuli, have been proposed to
reduce test–retest variability.19 All stimuli were pseudorandomly pre-
sented at a mean interval of 1/second/region and transiently (33 ms)
pulsed at a luminance of 250 cd/m2. The stimuli were projected on a
dim starburst background with a low spatial frequency radial grating
pattern at a luminance of 10 cd/m2 and included a small central fixation
cross. The radial pattern and a long, thin, vertical, white line bisecting
the fixation point were displayed to aid fusion. The subjects’ gaze
position was monitored during testing. Each test consisted of eight
segments of 30 seconds’ duration, with short rest breaks between
segments to allow for blinking and recovery. Separate video cameras
for each eye recorded pupil responses under infrared illumination.
Pupil responses were measured by fitting a circle to the lower three
fourths of the pupil margin providing some tolerance to ptosis.
Data Analysis
Recordings were exported from the field analyzer to a commercial
software program (MatLab R2009b; The MathWorks, Natick, MA) for
analysis. Linear regression was used to estimate the response ampli-
tude and time to peak from the raw pupillary responses.20 Multiple
linear regression is expressed as y  X  e, where y is the observed
response, X is the explanatory variable (independent variable),  are
the regression coefficients, and e represents the errors in the noise. We
fitted a log-normal function to the pupil response waveforms to analyze
the following parameters: contraction amplitudes (in micrometers)
and time to peak (in milliseconds).13,14,21 We used a previously de-
scribed procedure to overcome the effects of miotic pupils by normal-
izing the responses to the mean pupil size and subsequently scaling
them.14,17 The regressive method used to estimate mean pupil re-
sponses for each region generated standard errors for the measured
parameters,14,17 and provided a tolerance of 15% data loss from blinks
and fixation losses before a segment needed to be repeated.
Independent effects of treatment and subject variants on pupillary
responses were measured by fitting a multiple linear model to the
response amplitudes. Initially, the pupil response amplitudes were
transformed to decibels to stabilize the variance as follows:
AmpdB  10 log10Ampm
Time data were converted from seconds to milliseconds to aid
interpretation and did not require transformation. The effects of inde-
TABLE 1. Summary of Baseline Patient Data
ID Study Eye Age (y) Sex BCVA Diagnosis
Fundus Features
Drusen
Hemorrhage Size‡ Geographic Atrophy Size‡Number* Size†
401 OD 78 M 0.3 Occult 2 3 — —
402 OS 85 F 0.3 Occult 1 3 — —
403 OS 73 F 1.0 Classic 2 2 — 3
404 OD 68 F 0.5 Classic 1 1 2 —
405 OD 86 F § Occult — — 5 —
406 OD 72 F 1.3 Occult 3 3 5 —
407 OD 79 M 0.5 Classic — — — 5
408 OS 81 F 0.8 Occult 1 3 2 —
409 OD 78 F 0.3 Occult 2 3 — —
410 OD 79 F 0.8 Classic 1 3 — —
411 OD 72 M § Classic 1 3 — —
412 OD 79 M 1.0 Classic 1 2 — —
413 OD 76 M 0.2 Occult 3 2 — 3
414 OS 63 F 0.6 Occult 3 3 5 —
415 OS 85 F 0.3 Occult 2 3 — 5
416 OS 89 F 0.5 Occult 3 3 1 —
417 OS 80 F 0.1 Occult 2 3 2 —
418 OS 83 M 0.5 Classic 2 3 — —
419 OS 92 F 0.3 Occult 3 3 — —
420 OS 79 F 0.5 Occult 2 3 — —
* Drusen number: 1, 20; 2, 20; 3, 50.
† Drusen size: 1, 63 m; 2, 63 to 125 m; 3, 125 m.
‡ Lesion size: 1, 500 m; 2, 500 to 1000 m; 3, 1000 to 1500 m; 4, 1500 to 2000 m; 5, 3000 m.
§ BCVA, count fingers.
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pendent factors were measured by fitting them as contrasts to the
reference condition. The reference condition represented the mean
direct pupillary response (computed across eyes, pupils, and visual
field regions) of normal male subjects. This definition permitted the
significance of contrasting effects, such as being female, AMD, and
consensual responses to be calculated. To determine whether changes
in retinal function were observed more in the parafoveal than in the
foveal area, we compared the baseline and month 3 follow-up mfPOP
responses in three concentric rings (Fig. 1C) for the T24 stimulus: (1)
fovea, (2) parafovea, (3) perifovea (radii of 0.5°–3.0°, 3.3°–7.7°, and
8.0°–15°, respectively).
We used the leave-one-out method for estimating the area under
the curve (AUC) of receiver operator characteristic (ROC) plots to
determine the diagnostic status of subjects at pre- and posttreatment
examinations and the diagnostic performance of our stimulus proto-
cols, as previously described.13,14,17,21 The method used in this study
calculated ROC AUC values from the between-eye (asymmetric) re-
gional deviations relative to normal for both contraction amplitude and
time to peak responses from normative data, a method that has also
shown utility in mfVEPs.22
RESULTS
The mean pupillary contraction waveforms recorded at base-
line and after three consecutive months of intravitreal ranibi-
zumab injections from an 80-year-old woman are shown in
Figure 2. Each region of the stimulus ensemble was indepen-
dently modulated for each eye, producing separate direct and
consensual responses concurrently. Regional response ampli-
tudes in Figure 2A were found to be significantly reduced in
the nasal hemisphere of the left eye. Figure 2B shows an
improvement in mean contraction amplitudes at 3 months
after treatment. Her logMAR BCVA improved from 1 to 0.18,
and mean central retinal thickness (CRT) decreased from 340
to 258 m at 3 months of follow-up (cf. Figs. 2E and 2F).
After the follow-up period the visual acuities improved in 12
of 20 patients, with eight eyes measuring no improvement. The
mean baseline visual acuity value was 0.68  0.45 (mean  SD)
before treatment. After treatment, mean visual acuities did not
improve significantly from baseline (0.63  0.44, P  0.48).
Mean central retinal thickness decreased significantly after
three ranibizumab injections (P  0.001) from 340  83 m at
pretreatment to 236  36 m after treatment.
A multiple linear model was fitted to contraction amplitudes
(in decibels, Table 2) and times to peak (Table 3) responses to
determine the independent effect of AMD before and after
ranibizumab injections and of stimulus variables on pupillary
responses. Table 2 summarizes the reference condition, as
described in the Methods section, and the effects of the sub-
ject’s sex and exudative AMD at baseline and after three intra-
vitreal ranibizumab injections for contraction amplitudes cor-
rected for age. The average direct pupil contraction in normal
male subjects (reference) ranged from 4.91  0.30 dB (mean 
SE) for stimulus O44 to 3.94  0.30 dB for T24. Before treat-
ment, exudative AMD reduced mean response amplitudes by
between 0.71  0.17 dB (15%; P  0.0001) and 1.11 
FIGURE 1. Multifocal stimulus pat-
tern arranged in a dartboard layout
presented with all regions activated.
(A) The 44-region layout consisted of
five rings with overlapping polar
stimuli (actual stimuli are yellow).
(B) Half the stimuli from each hemi-
field are shown. (C, D) The 24-region
layout arranged in three non-overlap-
ping rings (labeled 1 to 3) with yel-
low stimuli. No stimuli infringed on
the horizontal or vertical midlines.
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0.24 dB (23%; P  0.00001) smaller than normals. After treat-
ment, the mean effect of exudative AMD on response ampli-
tudes measured 0.71  0.17 dB (P  0.0001) and 0.53 
0.22 dB (P  0.019) for stimulus O44 and T24, respectively.
Independent effects on time to peak responses (Table 3) were
more severely affected than contraction amplitudes with re-
sponses significantly more delayed than normal by 16.22 
2.10 ms (P  5  1014) for stimulus O44 and 18.82  3.0 ms
(P  5  1010) for stimulus T24. After 3 months of treatment,
delays due to AMD declined to 15.05  2.20 ms (P  5 
1011) and 7.45  3.15 ms (P  0.05) for stimulus O44 and
T24, respectively. Overall, time to peak responses in the
women were on average between 9.45  1.92 ms (P  5 
107) to 34.52  1.34 ms (P  5  10142) quicker than those
in the men. The mean consensual responses were not signifi-
cantly different from direct responses, consistent with previ-
ous studies.13,15 Stimulus T24 elicited the largest and most
significant effect for both contraction amplitudes and delays
before treatment in AMD patients; however, this trend was not
observed after treatment. A separate analysis identified addi-
tional delays to be significantly shorter after 3 months of
treatment for both stimuli O44 (P  5  104) and T24 (P 
FIGURE 2. Example of changes in
mfPOP and OCT during the course of
treatment in subject 417, who had
exudative AMD OS. (A) Mean direct
and consensual regional response re-
cordings to the T24 stimulus ensem-
ble at pretreatment. (B) Three months
after intravitreal ranibizumab injec-
tion. A downward deflection repre-
sents a pupil contraction response to
the stimuli presented at that location.
(C, E) OCT line scan and retinal
thickness map of the same eye dem-
onstrated severe retinal edema corre-
sponding to regions of reduced pu-
pillary response amplitudes. (D, F)
After 3 months of treatment, recov-
ery from edema temporal to the fo-
vea showed an improvement in affer-
ent contraction amplitude responses
in the nasal visual field, with direct
and consensual responses mostly
overlapping.
TABLE 2. Summary of Independent Effects of Variables on Pupil
Contraction Amplitudes Estimated by a Multiple Linear Model
Variable
O44 T24
dB SE P dB SE P
Reference 4.91 0.30  3.94 0.33 
Consensual 0.04 0.08 0.632 0.13 0.12 0.287
Female 0.16 0.10 0.118 0.05 0.14 0.729
AMD before treatment 0.71 0.17  1.11 0.24 
AMD after treatment 0.71 0.17  0.53 0.22 0.019
* P  5  104.
TABLE 3. Summary of Independent Effects of Variables on Time to
Peak Contraction
O44 T24
Variable ms SE P ms SE P
Reference 520 4.29  494 4.76 
Consensual 2.04 1.24 0.092 2.59 1.74 0.137
Female 34.52 1.34  9.45 1.92 
AMD before treatment 16.22 2.10  18.82 3.00 
AMD after treatment 15.05 2.20  7.45 3.15 0.018
* P  5  106.
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5  109). By contrast, there was only minor improvement in
mean contraction amplitude deviation at posttreatment for
protocol T24 (P  0.017).
Presenting region-by-region amplitude and delay deviations
from normal responses (Fig. 3) for stimulus T24 allows for
affected locations to be investigated over time. Responses from
both eyes were combined so that each visual field location
represented a similar nasotemporal region in each eye. The
result at the baseline visit pointed to retinal dysfunction in
patients with exudative AMD. Figures 3A and 3C indicate that
the longest delays occur within the central 3° of fixation.
Figure 3B shows shorter mean additional delays in exudative
AMD (shown as darker grays) and a bias toward less delay in
the nasal field, evident at 3 months after treatment. To deter-
mine whether retinal dysfunction was deteriorating more in
the foveal than in the parafoveal area, we analyzed the mean
effects at baseline and 3 months using averages across the
three concentric rings of the T24 stimulus (Figs. 3C, 3F). Figure
3C demonstrates additional delay effects reaching a peak in
ring 1 corresponding to the foveal region (3° retinal eccen-
tricity). On average, additional delay effects at 3 months (Fig.
3C) were significantly smaller for all concentric rings (P 
0.05, paired t-test). Average contraction amplitude deviations
were largest for ring 2 (Fig. 3F) at baseline, with seven regions
within the parafovea having significantly smaller responses
(P  0.05) than normal (Fig. 3D). An improvement in mean
response amplitude deviation was evident at posttreatment
follow-up (Figs. 3E, 3F), but reached significance only in ring 2.
Thus the region-wise analysis was more revealing than the ring
analysis.
We also examined the predictive capacity of mfPOP by
fitting an effect for subjects who demonstrated improved acu-
ity or reduced CRT at 3 months. On average, subjects who
displayed a decrease in CRT contracted by an additional 0.54 
0.15 dB (11.4%) and were 21.3  2.6 ms quicker to stimulus
T24 after 3 months (both P  0.005). When the correlation
between mfPOP amplitude and time to peak responses and
BCVA were analyzed, no significant correlation was found
before and after treatment examinations (P  0.76, P  0.73,
P  0.58, P  0.57, respectively). Figure 4 shows the baseline
mean regional amplitude deviation profile of subjects who had
reductions in CRT at 3 months for stimulus O44 (Fig. 4A) and
T24 (Fig. 4B). The results show a strong consensus between
stimulus protocols with small but significantly larger than nor-
mal mean responses (lightest regions) in inferior peripheral
regions.
The diagnostic power achieved in the mfPOP stimulus pro-
tocols for exudative AMD at baseline and posttreatment are
shown in Table 4. This also showed the value of a higher
resolution analysis of the visual field. AUC values for response
FIGURE 3. Measures of regional mean pupil response deviations from normal, before and 3 months after intravitreal ranibizumab injection. The
means are quantified by a multiple regression model where the subject’s sex and consensual response were also factors. Contraction amplitudes
and delays from both eyes have been combined by reversing the results of the right eye such that each region represents the identical segment
of the field for each eye; thus, the temporal field is on the left. The background gray level represents a deviation of 0. (A) Mean additional delays
caused by exudative AMD subjects at baseline, thus longer delays are depicted in lighter gray. The delays of the brightest 10 regions in the field
reached statistical significance. (B) Mean additional delays by region 3 months after onset of treatment. No regions were statistically more delayed
than normal. (C) Relationship between mean additional delays at baseline and 3 months across increasing ring eccentricity. All rings showed a
significant reduction of response delays at 3 months (P  0.05). (D) The mean amplitude deviations for exudative AMD subjects at baseline. The
seven darkest regions that fall within the parafovea were significantly reduced in amplitude. (E) Mean amplitude deviations at 3 months after
treatment. Contraction amplitude deviations from 3 regions reached significance across the central 15° of visual field. Six regions from the outer
ring appeared to be hypersensitive, but that effect did not reach statistical significance. (F) Relationship between mean amplitude deviations at
baseline and 3 months according to rings. A statistically significant change in amplitude deviations was observed only in ring 2 at the second
examination.
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delays, illustrated that stimulus O44 achieved the highest diag-
nostic performance at both baseline (100%  0.0%) and month
3 (100%  0.0%) examinations. Evaluating the mean percent
AUC and SE obtained for the worst-deviating (N-worst) 2, 10,
and all regions of the visual field suggests that restricting the
analysis to the 1 or 2 worst-performing regions improves diag-
nostic performance and confirms our expectation of the pres-
ence of localized severe retinal dysfunction in exudative AMD.
We also assessed diagnostic accuracy using constriction ampli-
tudes and found that it did not perform as well at baseline
(96.9%  3.1%) but was consistent with time to peak devia-
tions after treatment (96.8%  4.4%).
DISCUSSION
This study has investigated changes in retinal function as mea-
sured by mfPOP in eyes with exudative AMD before and after
intravitreal ranibizumab therapy for CNV. The method identi-
fied functional impairment in contraction amplitudes and time
to peak responses within the central 15° of fixation. A signifi-
cant reduction in CRT (P  0.001) and additional delays for
stimulus protocol O44 (P  5  104) and T24 (P  5  109)
were observed at 3 months after treatment. In contrast with
earlier studies,6–8 we did not observe a significant mean im-
provement in BCVA after treatment; however, baseline vision
was better in this series than in the pivotal trials.
The results of our study suggest that intravitreal ranibi-
zumab injections had larger effects on time to peak responses
than on contraction amplitudes. At baseline (Fig. 3A), we
identified 10 visual field regions that were significantly delayed
(P  0.05) from normal, whereas at the 3-month follow-up,
there were no regions significantly delayed, although we did
observe a bias toward shorter delays in the nasal visual field
(Fig. 3B). Contraction amplitude deviations were less informa-
tive than response delays, with only a marginally significant
reduction in the mean effect of exudative AMD after 3 months
of treatment (Table 2) for stimulus T24. Mean regional ampli-
tude deviations from normative data peaked in the parafoveal
region (ring 2) of the visual field (Figs. 3D, 3F) confirming the
results of our first published mfPOP study of exudative AMD,23
which is in accordance with histopathological findings of the
initial site of photoreceptor loss (0.5–2 mm from the fovea) in
AMD.24 What was striking was the three regions demonstrating
hypersensitivity in contraction amplitudes (Fig. 3E) in the
outer ring of exudative AMD subjects after ranibizumab ther-
apy. Previous studies from our laboratory have found positive
mean effects for peripheral contraction amplitude deviations in
diabetic retinopathy14 and exudative AMD.23 Of particular in-
FIGURE 4. Baseline mean regional
contraction amplitude deviations rep-
resenting subjects who had improve-
ments in CRT after ranibizumab ther-
apy. (A) Stimulus O44 shows a bias
toward larger response amplitudes in
the inferior hemifield with six regions
reaching significance (*P  0.05). (B)
Seven regions in the inferior periph-
eral annulus of stimulus T24 produced
significantly larger responses than nor-
mal.
TABLE 4. ROC Percentage AUC of Time to Peak Contraction (Delay) Presented as the Values at Baseline
and after Treatment
O44 T24
AUC (n  2) AUC (n  10) AUC (n  All) AUC (n  2) AUC (n  10) AUC (n  All)
Baseline 100  0.0 95.0  3.9 94.2  4.0 95.8  4.1 85.8  5.5 82.3  6.4
Month 3 100  0.0 98.8  1.1 96.8  2.2 91.1  6.0 83.8  7.0 79.3  7.9
ROC AUC data (mean %  SE) of 20 eyes with exudative AMD at baseline and 3 months after
treatment for stimulus O44 and T24 are presented. The next three columns to the right present AUC and
SE results for the 2, 10, and all worst deviations from normal (N-worst). All deviations are equivalent to
using the mean defect in perimetry. Diagnostic performance was assessed on between-eye deviations from
normative data for time to peak contraction (delay). This result was determined by measuring the
differences in deviations at the same VF region between eyes. The diagnostic performance of stimulus O44
was greater than T24 for all N-worst deviations considered.
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terest are the baseline response deviations of subjects who had
significant reductions in CRT over time (Figs. 4A, 4B). The
results, if confirmed in a larger group of subjects, suggest that
increased response amplitudes in the inferior peripheral re-
gions may be a unique functional marker for predicting CRT
outcomes after ranibizumab therapy. We propose that in an
attempt to improve central retinal sensitivity a global mecha-
nism may be attempting to increase response gain generally to
compensate for disease, which acts to boost responses from
healthy peripheral regions. Detailed investigation into changes
in retinal sensitivity measured by mfPOP and changes in retinal
structure are needed, to confirm that hypothesis.
The observed disparity between response delays and ampli-
tudes may reflect disruptions to interneurons in diseases of the
outer retina.25–27 Temporal responses may be affected to a
greater extent than other parameters of the pupillary signal.
This imbalance has been reported in mfERG,28 and multifocal
pupillography studies in patients with retinitis pigmentosa.9
Another hypothesis is that morphologic changes in the RPE/
Bruch’s membrane complex, such as retinal pigment epithelial
abnormalities and drusen, both known to significantly reduce
macular sensitivity,29 may contribute to a timing delay. A lim-
itation of our study is the difficulty of assessing the degree of
overlap between changes in retinal morphology and visual
dysfunction.
Superimposition of the regional mfPOP data on the OCT
and fundus images must be examined to determine the corre-
lation between structure and function.
Kiss et al.6 investigated the effects of ranibizumab therapy
on central retinal sensitivity with microperimetry in patients
with CNV secondary to exudative AMD. They found that mean
retinal sensitivity improved from baseline, for the foveal center
(0°) and paracentral test locations (3.5° retinal eccentricity),
after 3 months of ranibizumab therapy. At the extrafoveal
regions (7.9°) a decrease in sensitivity was observed after
ranibizumab therapy. A separate study by the same author
investigating combination verteporfin photodynamic therapy
(PDT) and ranibizumab found no significant changes in mean
retinal sensitivity outside the regions treated with PDT.8 They
suggested that ranibizumab had no measurable effect on re-
gions of healthy retina. In agreement with Kiss et al.,6,8 we
found improvements in the overall mean effect of exudative
AMD on contraction amplitudes and time to peak at 3 months,
with reductions in amplitude deviations less pronounced be-
yond 7.7° retinal eccentricity (Fig. 3F). In addition, differ-
ences may exist in the vulnerability of ganglion cell type and
organization between the visual and pupil pathways in outer
retinal disease, manifesting distinct patterns of dysfunction for
mfPOP and microperimtrey. An apparent advantage of mfPOP
over other objective perimeters (mfVEP and mfERG) lies in its
noninvasive nature, minimal setup, and brief testing time.
Stimulus protocols with high-resolution layouts (e.g., 44
regions/field) produced smaller effects for exudative AMD on
contraction amplitudes than low-resolution stimuli (T24). By
contrast the relatively high resolution of contraction delays for
the O44 stimuli was definitely more diagnostically useful that
the lower resolution T24 ensemble (Table 4). We have at-
tempted higher resolution stimuli having 24 or 44 regions
within the central 20°, but these so far have provided poor
signal to noise ratios.15 At the same time, large blurry stimuli
are tolerant of misrefraction and have been suggested to re-
duce test–retest variability.19 AUC values were a bit lower after
treatment (Table 4), seemingly quantifying the improvement in
retinal function (e.g., Fig. 2).
In summary, we describe the first investigation of macular
dysfunction by mfPOP after ranibizumab therapy. Although
previous studies reported effects on retinal sensitivity, we
observed clinically meaningful changes in the temporal com-
ponent of the regional pupillary response and demonstrated
the diagnostic potential of mfPOP. The presence of increased
response amplitudes in the inferior peripheral regions was the
best predictor of improvement in CRT after treatment. Prog-
nostic markers identifying potential recovery of function will
gain significance for optimizing patient selection as new treat-
ment options for exudative AMD develop. In addition, signifi-
cant improvement in regional temporal responses after treat-
ment may help guide retreatment strategies. A combined
mfPOP and CRT approach may allow us to monitor patients
more precisely and initiate treatment earlier. Longitudinal pro-
spective studies with larger patient numbers are needed, to
determine whether improvements in mfPOP responses are
maintained during ranibizumab treatment.
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